Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist
暂无分享,去创建一个
Robert C. Glen | Joseph Cheriyan | Anthony P. Davenport | Janet J. Maguire | Mervyn Singer | Rubben Torella | Ian B. Wilkinson | Alex Dyson | R. Glen | M. Singer | I. Wilkinson | Rubben Torella | A. Davenport | J. Maguire | A. Dyson | Aimee L. Brame | Peiran Yang | Peiran Yang | J. Cheriyan | Aimée L. Brame
[1] W. Koch,et al. Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy , 2014, Expert review of cardiovascular therapy.
[2] R. Skoumal,et al. Apelin Increases Cardiac Contractility via Protein Kinase Cε- and Extracellular Signal-Regulated Kinase-Dependent Mechanisms , 2014, PloS one.
[3] Arthur Christopoulos,et al. Quantification of Ligand Bias for Clinically Relevant β2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy , 2014, Molecular Pharmacology.
[4] J. Violin,et al. The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. , 2013, American journal of physiology. Heart and circulatory physiology.
[5] L. Huson,et al. Sustained Cardiovascular Actions of APJ Agonism During Renin–Angiotensin System Activation and in Patients With Heart Failure , 2013, Circulation. Heart failure.
[6] Arthur Christopoulos,et al. Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.
[7] Guodong Liu,et al. A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[8] E. Ashley,et al. APJ ACTS AS A DUAL RECEPTOR IN CARDIAC HYPERTROPHY , 2012, Nature.
[9] Howard Y. Chang,et al. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. , 2011, The Journal of clinical investigation.
[10] R. Glen,et al. Discovery of a Competitive Apelin Receptor (APJ) Antagonist , 2011, ChemMedChem.
[11] T. Quertermous,et al. Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary Hypertension , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[12] G. Colombo,et al. Investigating dynamic and energetic determinants of protein nucleic acid recognition: analysis of the zinc finger zif268-DNA complexes , 2010, BMC Structural Biology.
[13] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[14] T. Bonner,et al. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function , 2010, Pharmacological Reviews.
[15] A. Davenport,et al. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man , 2010, British journal of pharmacology.
[16] Maarten G. Wolf,et al. g_membed: Efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation , 2010, J. Comput. Chem..
[17] B. Maigret,et al. By Interacting with the C-terminal Phe of Apelin, Phe255 and Trp259 in Helix VI of the Apelin Receptor Are Critical for Internalization* , 2010, The Journal of Biological Chemistry.
[18] T. McDonagh,et al. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. , 2010, Journal of cardiac failure.
[19] Alexander D. MacKerell,et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. , 2010, The journal of physical chemistry. B.
[20] D. Newby,et al. Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure , 2010, Circulation.
[21] A. Davenport,et al. [Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease , 2009, Hypertension.
[22] D. Langelaan,et al. Headgroup-Dependent Membrane Catalysis of Apelin−Receptor Interactions Is Likely , 2009, The journal of physical chemistry. B.
[23] N. Weissmann,et al. Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[24] A. Leite-Moreira,et al. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. , 2009, American Journal of Physiology. Heart and Circulatory Physiology.
[25] T. Reddy,et al. Structural insight into G-protein coupled receptor binding by apelin. , 2009, Biochemistry.
[26] L. Rohde,et al. Bradykinin or Acetylcholine as Vasodilators to Test Endothelial Venous Function in Healthy Subjects , 2008, Clinics.
[27] D. Webb,et al. Vascular effects of apelin in vivo in man. , 2008, Journal of the American College of Cardiology.
[28] V. Cuervas-Mons,et al. Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids , 2007, Regulatory Peptides.
[29] M. Singer,et al. Tissue oxygen monitoring in rodent models of shock. , 2007, American journal of physiology. Heart and circulatory physiology.
[30] B. Masri,et al. The Apelin Receptor Is Coupled to Gi1 or Gi2 Protein and Is Differentially Desensitized by Apelin Fragments* , 2006, Journal of Biological Chemistry.
[31] E. Ashley,et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure , 2006, European journal of heart failure.
[32] B. Geng,et al. Apelin protects myocardial injury induced by isoproterenol in rats , 2006, Regulatory Peptides.
[33] E. Ashley,et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. , 2005, Cardiovascular research.
[34] M. Berry,et al. Apelin Has In Vivo Inotropic Effects on Normal and Failing Hearts , 2004, Circulation.
[35] F. Horkay,et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. , 2003, Biochemical and biophysical research communications.
[36] R. Pomerantz,et al. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. , 2003, Biochemistry.
[37] R. Pomerantz,et al. Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJ. , 2003, Virology.
[38] Robert P. Davis,et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin , 2003, Journal of neurochemistry.
[39] E. Frohlich,et al. Echocardiographic measurement of cardiac output in rats. , 2003, American journal of physiology. Heart and circulatory physiology.
[40] J. Rysä,et al. Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility , 2002, Circulation research.
[41] J. Maguire. Endothelin-converting enzyme activity in vascular smooth muscle preparations in vitro. , 2002, Methods in molecular biology.
[42] D. Webb,et al. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. , 2001, British journal of clinical pharmacology.
[43] D. Webb,et al. Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure , 2001, Circulation.
[44] Berk Hess,et al. GROMACS 3.0: a package for molecular simulation and trajectory analysis , 2001 .
[45] M. Palkovits,et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain , 2001, Journal of neurochemistry.
[46] Shelagh Wilson,et al. Visualizing differences in ligand‐induced β‐arrestin–GFP interactions and trafficking between three recently characterized G protein‐coupled receptors , 2001, Journal of neurochemistry.
[47] D. Webb,et al. A novel S‐nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium , 2000, Clinical pharmacology and therapeutics.
[48] Y. Sugita,et al. Replica-exchange molecular dynamics method for protein folding , 1999 .
[49] X. Daura,et al. Peptide Folding: When Simulation Meets Experiment , 1999 .
[50] S. Hinuma,et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. , 1998, Biochemical and biophysical research communications.
[51] K. Chou. Prediction and classification of α‐turn types , 1997 .
[52] K C Chou. Prediction and classification of alpha-turn types. , 1997, Biopolymers.
[53] A. Lombardi,et al. Discovering protein secondary structures: Classification and description of isolated α‐turns , 1996 .
[54] F. Mee,et al. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. , 1996, Blood pressure monitoring.
[55] A. Lombardi,et al. Discovering protein secondary structures: classification and description of isolated alpha-turns. , 1996, Biopolymers.
[56] A Sali,et al. Comparative protein modeling by satisfaction of spatial restraints. , 1996, Molecular medicine today.
[57] D. van der Spoel,et al. GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .
[58] Andrej ⩽ali,et al. Comparative protein modeling by satisfaction of spatial restraints , 1995 .
[59] A. Davenport,et al. ETA receptor‐mediated constrictor responses to endothelin peptides in human blood vessels in vitro , 1995, British journal of pharmacology.
[60] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[61] S. Gardiner,et al. Differential effects of (±)‐dobutamine and human α‐CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats , 1991, British journal of pharmacology.
[62] H. Drexler,et al. Central and Regional Vascular Hemodynamics Following Intravenous Milrinone in the Conscious Rat: Comparison with Dobutamine , 1987, Journal of cardiovascular pharmacology.
[63] W. H. Aellig. Methods for studying drug effects on superficial human veins. , 1985, Methods and findings in experimental and clinical pharmacology.
[64] W. Kabsch,et al. Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.
[65] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[66] J. Richardson,et al. The anatomy and taxonomy of protein structure. , 1981, Advances in protein chemistry.
[67] R. Spurrell,et al. Haemodynamic effects of dobutamine with special reference to myocardial blood flow. A comparison with dopamine and isoprenaline. , 1979, British heart journal.
[68] W. H. Aellig. Use of a linear variable differential transformer to measure compliance of human hand veins in situ [proceedings]. , 1979, British journal of clinical pharmacology.